INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Stefa		aan Decorte
Art Unit		
Examiner Name		
Attorney Docket Number		AP108-06

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines whe Relevant Passages or Rele Figures Appear			
	1										
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button. Add										
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d buttor			
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*			Kind Code ⁴		Applicant of cited		where Rele	or Relevant	T5		
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove									_		
Examiner Initials*	Cite No	Include name of the ai (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o					Тs

Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor Stefaan Decorte STATEMENT BY APPLICANT Art I Init (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 4P108.06

	1	HAIPING XU, "A Model-Based Approach for Development of Multi-Agent Software Systems", Online! March 2003, pages 1-147, Chicago, Retrieved from the Internet: www.os.umassd.edu/grup/Papers/U/C/PhD/Thesis.pdf>				
	2	MAS LABORATORY, DEPARTMENT OF COMPUTER SCIENCE, UNIVERSITY OF MASSACHUSEITS AT AMHERIST, "Java Agent Framework Howl", O'maine 23 March 2003, APR022505091, Retired from the Internet: http://www.da.roiv.org/web20030539516961 http://www.da.roiv.com/science/				
	3	WOOD M. F. ET AL., "An overview of the multagent systems engineering methodology", AGENT-ORIENTED SOFTWARE ENGINEERING, FIRST INTERNATIONAL WORKSHOP, AGSE 2000, REVISED PAPERS (LECTURE NITCES IN COMPUTER SCIENCE VOL. 1957) SPRINGER-VERLAG BERLIN, GERMANY, 2001, pages 207-221, XP002350503				
If you wish to add additional non-patent literature document citation information please click the Add button Add						

EXAMINER SIGNATURE

Date Considered Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

Application Number Filing Date Filing Date Filing Date First Number Inventor Stefan Decords Art Unit Examiner Name Attorney Docket Number AP109-06

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c)(d).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David A. Guerra/	Date (YYYY-MM-DD)	2006-08-09
Name/Print	David A. Guerra	Registration Number	46443

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.